Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: MRA(Tocilizumab)
- Registration Number
- NCT00144586
- Lead Sponsor
- Chugai Pharmaceutical
- Brief Summary
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA220JP or MRA221JP.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 MRA(Tocilizumab) -
- Primary Outcome Measures
Name Time Method 20% improvement based on the American College of Rheumatology (ACR) criteria compared with the baseline value in the previous study. throughout study
- Secondary Outcome Measures
Name Time Method Time courses for DAS28, for ACR20%, 50%, and 70% improvement, and for each ACR core set variable. Week 0, then every 4 Week